nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea
Company profile
Ticker
NBTX
Exchange
Website
CEO
Laurent Levy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NBTX stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
17 Apr 24
6-K
Voting Rights and Shares Capital of the Company
10 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Nanobiotix to Present at Upcoming Investor Conferences in March
6 Mar 24
6-K
Voting Rights and Shares Capital of the Company
13 Feb 24
6-K
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
31 Jan 24
6-K
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
29 Jan 24
6-K
Voting Rights and Shares Capital of the Company
11 Jan 24
6-K
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
26 Dec 23
6-K
Voting Rights and Shares Capital of the Company
13 Dec 23
Latest ownership filings
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G/A
Qatar Investment Authority
8 Feb 24
SC 13G/A
JOHNSON & JOHNSON
2 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
SC 13G
Johnson & Johnson Innovation - JJDC, Inc.
16 Nov 23
SC 13G
Qatar Investment Authority
8 Nov 23
SC 13G/A
BAILLIE GIFFORD & CO
2 Feb 23
SC 13G/A
BAILLIE GIFFORD & CO
20 Jan 23
SC 13G/A
Artal International S.C.A.
11 Feb 22
SC 13G/A
BAILLIE GIFFORD & CO
26 Jan 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
16.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 5 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 30.38 bn |
Total shares | 7.54 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Artal International S.C.A. | 3.07 mm | $24.86 mm |
Baillie Gifford & Co | 1.94 mm | $16.94 bn |
Artal | 1.00 mm | $8.75 mm |
JNJ Johnson & Johnson | 959.64 k | $8.40 bn |
Perceptive Advisors | 555.07 k | $4.86 bn |
Susquehanna International | 11.20 k | $98.01 mm |
UBS UBS Group AG - Registered Shares | 3.81 k | $33.30 mm |
MS Morgan Stanley | 1.70 k | $14.88 mm |
Qube Research & Technologies | 700.00 | $6.13 mm |
Rhumbline Advisers | 33.00 | $288.00 k |
News
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
11 Apr 24
Nanobiotix Announces Completion Of Phase 1 Dose Escalation And NBTXR3 Recommended Phase 2 Dose For The Treatment Of Inoperable, Recurrent Lung Cancer In Patients Amenable To Re-Irradiation
2 Apr 24
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
18 Mar 24
Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
18 Mar 24
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
Press releases
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
17 Apr 24
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
2 Apr 24
Nanobiotix to Present at Upcoming Investor Conferences in March
6 Mar 24
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
31 Jan 24
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
29 Jan 24